[Skip to Content]
[Skip to Content Landing]
Views 410
Citations 0
Invited Commentary
May 2017

Are Novel Anticoagulants Worth Their Cost?

Author Affiliations
  • 1Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California
  • 2Department of Medicine, Stanford University School of Medicine, Stanford, California
JAMA Cardiol. 2017;2(5):534-535. doi:10.1001/jamacardio.2017.0126

Cost-effectiveness analyses began to appear in medical journals more than 40 years ago and have proliferated greatly since then. Methodologic standards were established 20 years ago and have been recently updated.1 Economic considerations are just now being introduced into clinical practice guidelines.2 The field of economic evaluation of health interventions is maturing, but observers may rightfully ask: what is the point of all these studies? Why should we do them in the first place, and how can we use the results?

First Page Preview View Large
First page PDF preview
First page PDF preview
×